Table 1.
Monoclonal antibodies approved by the US food and drug administration for the treatment of cancer
| Year | International non-proprietary name/Trade name | Target | Indication |
| 1997 | Rituximab/Rituxan | CD20 | B-cell lymphoma |
| 1998 | Trastuzumab/Herceptin | HER2 | Breast cancer |
| 2001 | Alemtuzumab/Campath | CD52 | Chronic lymphocytic leukemia |
| 2002 | Ibritumomab tiuxetan/Zevalin | CD20 | B-cell lymphoma |
| 2003 | Tositumomab/Bexxar | CD20 | B-cell lymphoma |
| 2004 | Bevacizumab/Avastin | VEGF | Colon, lung, breast and renal cancer |
| 2004 | Cetuximab/Erbitux | EGFR | Colon; lung cancer |
| 2006 | Panitumumab/Vectibix | EGFR | Colon cancer |
| 2009 | Ofatumumab/Arzerra | CD20 | Chronic lymphocytic leukemia |
| 2011 | Ipilimumab/Yervoy | CTLA-4 | Melanoma |
Note: The immunoconjugate gemtuzumab ozogamicin (Mylotarg®) was approved by the US Food and Drug Administration in 2000 and withdrawn from marketing in 2010. Catumaxomab (Removab®) was approved in the European Union in 2009.